News & Press Releases |

Press Release: October 16, 2019
Acquist Therapeutics to Present at 2019 BIO Investor Forum

Press Release: January 17, 2019
Acquist Announces Issuance of Two U.S. Patents Covering its Drug Library of Novel Small Molecules

Press Release: November 14, 2018
Acquist Presents Positive Results for Its Lead NASH Drug, ACQT1127, at The Liver Meeting: Central Role for Acquist Drugs that Target Lipogenesis and Inflammation | Poster

Press Release: October 2, 2018
Acquist Therapeutics to Present Scientific Results for Lead Clinical Drug in Gout | Abstract

Press Release: September 25, 2018
Acquist Therapeutics to Provide Update on Lead Programs for Treating NASH and Gout

Press Release: October 11, 2017
Relburn-Metabolomics to Present Developments in Lead Programs for NASH and Gout

Press Release: October 6, 2017
Relburn-Metabolomics Appoints Renowned Experts in Nonalcoholic Steatohepatitis (NASH) to its Scientific Advisory Board

Press Release: May 19, 2017
Relburn-Metabolomics Announces a Second Drug Development Program in a Highly Prevalent Liver Disease: Company to Present at NJ BIO Partnering Conference on May 23, 2017

Press Release: October 17, 2016
Relburn-Metabolomics Files Patents on Bifunctional Nanomolar Inhibitors of Gout Target Enzymes: Company to Present at BIO Investor Forum in San Francisco October 18, 2016

Press Release: August 1, 2016
Relburn-Metabolomics Files Fourth Patent for its Anti-Gout Drug Portfolio: Initial Portfolio Patent Also Receives U.S. Notice of Allowance

Press Release: October 20, 2015
Relburn-Metabolomics to Outline Research Progress at BIO Investor Forum

Press Release: June 9, 2015
Relburn-Metabolomics to Present at BIO International 2015

Press Release: January 7, 2015
Relburn-Metabolomics to Present at Biotech Showcase 2015

Press Release: October 6, 2014
Relburn-Metabolomics to Report Scientific Progress and Clinical Plans for Anti-Gout Program at Two Major Conferences | Abstract

Press Release: June 3, 2014
Relburn-Metabolomics to Report Clinical and Scientific Progress in Anti-Gout Program at the European Congress on Rheumatology | Presentation

Press Release: January 7, 2014
Relburn-Metabolomics to Outline Clinical Development Plans for Lead Anti-Gout Product

Copyright © 2020 Acquist Theraputics, Inc.^® 

Website by CreatedByEric